Sepsis Clinical Trial
Official title:
Experimental Determination of Atot en Ka in the Critically Ill
To diagnose acid base disturbances using blood gas analysis, multiple approaches are
currently in use. These include the classic Henderson-Hasselbach bicarbonate approach and
the physiochemical approach by Stewart1. All have shown to be mathematically compatible2.
Diagnosing the metabolic component of acid base disturbances relies on the assessment of the
so called ion gaps: the anion gap for the classic acid-base approach and the strong ion
difference (SID) for the Stewart approach. This gap may unveil unidentified anions to
provide a more accurate diagnosis. In particular they allow differentiating between relative
hyperchloremia and other strong ions such as lactate, ketones, salicylates, citrate and
ethylene glycol3.
The accuracy of both gaps relies on the estimation of the weak acid dissociation: A-. This
A- is dependent on the total concentration of weak acids (Atot) of which albumin is the most
important and the effective dissociation constant for these (Ka), which determines the
dissociated fraction of the Atot. This dissociation fraction needs to be accounted for in
the ion gaps. This is reflected in the recommendation to correct the anion gap for albumin
and incorporated in the SID which includes a factor for albumin by design3,4. However, the
correction factor for albumin is currently based on data from animals and healthy
volunteers4-9. In the critically ill albumin and protein content are very different compared
to healthy volunteers, most notably in sepsis. Further, it is unknown if subunit composition
of albumin is different in these patients. In addition, different protein species may be
either up or downregulated in the critically ill1,8,9.Therefore from a pathophysiological
point of view Atot and Ka and thus A- may differ in the critically ill. However it has not
been previously investigated if and to what extent these matters affect Atot and Ka and
therefore A- in this population.
In addition, previous studies looking into this values showed a higher than expected value
of unmeasured anions from the gap calculations. Despite rigorous experimental effort
including high performance liquid chromatography, the origin of these unmeasured anions have
not yet been elucidated17-20. However if the assumptions made in the Stewarts approach would
not be valid, the existence of these unknown anions may have to be questioned.
Thus it is of great interest to experimentally determine the exact contribution of the weak
acids and their dissociation in sepsis. This could have major implications for these
patients because different assumptions will ultimately lead to alterations in their
calculated anion gap or SID. This may reduce unnecessary diagnostic test, alter final
diagnosis and hence alter therapy.
In this study the investigators aim to experimentally determine the Atot and Ka and thus
their dissociated fraction A- in critically ill septic patients admitted to the intensive
care unit by using in vitro CO2 tonometry, plasma dialysis and Marquardt regression
analysis. In addition, as a control the investigators will do the same for patients admitted
to the intensive care after routine cardiac surgery. Furthermore Atot and Ka values for both
groups will be compared to values obtained from human volunteers in a previous study4.
To achieve this, the investigators will plot CO2 versus pH titration curves from plasma
samples of these patients. The investigators will then use Marquardt nonlinear regression
analysis to quantify Atot and Ka and the SID by simultaneously solving for these
parameters21. To make the quantification for Atot and Ka more robust, the investigators will
also perform the same experiments after dialyzing the obtained plasma samples against a
crystalloid solution of known composition in order to eliminate errors related to estimation
of the SID. Finally, Atot and Ka values for both groups will be compared to values obtained
from human volunteers in a previous study4. For application in the bicarbonate and base
excess centred frameworks, Atot and Ka values will be related to albumin and protein content
to update the correction factor for the anion gap in critically ill.
Status | Completed |
Enrollment | 30 |
Est. completion date | May 2014 |
Est. primary completion date | May 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria septic patients: - >18 years of age - severe septic shock according to SIRS criteria - SOFA score > 9 - not pregnant Exclusion Criteria septic patients: - parenteral nutrition Inclusion criteria cardiac surgery patients - Elective Coronary arterial bypass graft (CABG), Aortic valve replacement (AVR) or combined CABG/AVR - Not pregnant - Admission from home - Euroscore < 7 |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Netherlands | VU University medical Center | Amsterdam | Boelelaan 1117 |
Lead Sponsor | Collaborator |
---|---|
VU University Medical Center |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The absolute amount of weak acids in plasma (Atot) in critically ill patients | The Atot in healthy volunteers was previously investigated. The Atot in critically ill patients might differ from this. Therefore the investigators are interested in the absolute amount of weak acids in critically ill patients. | within 24 hours after admission | No |
Primary | The weak acid dissociation constant (A-) in critically ill patients. | The A- in healthy volunteers was previously investigated. The A- in critically ill patients might differ from this. Therefore the investigators are interested in the weak acid dissociation constant in critically ill patients. | within 24 hours after admission | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |